Drugs / TIDUTAMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03411915 | Jan 2018 → Oct 2021 | digestive system neoplasm, neuroendocrine neoplasm | Xencor, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04590781 | May 2021 → Mar 2022 | cutaneous neuroendocrine carcinoma, small cell lung carcinoma | Xencor, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-03-01 | Xencor, Inc. | Results Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting xencor.com ↗
Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIDUTAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298132 ↗ |
| Known as | XmAb18087 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03411915 ↗ |
| Modality | Monoclonal antibody | “monoclonal bispecific antibody” NCT03411915 ↗ |